Carolina L Haass-Koffler1,2,3, Roberta Perciballi2,4, Zoe E Brown2, Mary R Lee3, William H Zywiak2,5, Jonathan Kurtis6, Robert M Swift1,7, Lorenzo Leggio2,3,8. 1. Department of Psychiatry and Human Behavior, Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island. 2. Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island. 3. Division of Intramural Clinical and Biological Research, Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. 4. Sapienza Università, Rome, Italy. 5. Mathematics Department, Bryant University, Providence, Rhode Island. 6. Department of Pathology and Laboratory Medicine, Brown University, Smithfield, Rhode Island. 7. Veterans Affairs Medical Center, Providence, Rhode Island. 8. Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland.
Abstract
BACKGROUND AND OBJECTIVES: In this secondary analysis of a pilot clinical trial with individuals with alcohol and nicotine use disorders, we investigate the relationship between serum concentrations of oxytocin, β-endorphin, melatonin, α-melanocyte-stimulating hormone, substance P, and orexin, with objective biomarkers (salivary cotinine and serum γ-glutamyl transferase [GGT]) as well as with self-reported smoking and alcohol drinking. METHODS: Biomarkers for a total of N = 19 participants were analyzed using multiplexed, competitive format immune-assay (peptides) and enzyme competitive immunoassay (saliva). A regression analysis using Pearson's correlation coefficient was utilized to determine correlations. We controlled for multiple comparisons, checked for collinearities, and ran two-sided statistical tests. RESULTS: We found significant positive correlations for cotinine and oxytocin (P = .002), β-endorphin (P = .008), and orexin (P < .001), but not for either GGT or self-reported smoking or alcohol drinking. CONCLUSION AND SCIENTIFIC SIGNIFICANCE: These preliminary results suggest a relationship between cotinine and oxytocin, β-endorphin, and orexin, which opens up new potential hypotheses on the potential role of these endocrine pathways in tobacco smokers. (Am J Addict 2021;30:88-91).
BACKGROUND AND OBJECTIVES: In this secondary analysis of a pilot clinical trial with individuals with alcohol and nicotine use disorders, we investigate the relationship between serum concentrations of oxytocin, β-endorphin, melatonin, α-melanocyte-stimulating hormone, substance P, and orexin, with objective biomarkers (salivary cotinine and serum γ-glutamyl transferase [GGT]) as well as with self-reported smoking and alcohol drinking. METHODS: Biomarkers for a total of N = 19 participants were analyzed using multiplexed, competitive format immune-assay (peptides) and enzyme competitive immunoassay (saliva). A regression analysis using Pearson's correlation coefficient was utilized to determine correlations. We controlled for multiple comparisons, checked for collinearities, and ran two-sided statistical tests. RESULTS: We found significant positive correlations for cotinine and oxytocin (P = .002), β-endorphin (P = .008), and orexin (P < .001), but not for either GGT or self-reported smoking or alcohol drinking. CONCLUSION AND SCIENTIFIC SIGNIFICANCE: These preliminary results suggest a relationship between cotinine and oxytocin, β-endorphin, and orexin, which opens up new potential hypotheses on the potential role of these endocrine pathways in tobacco smokers. (Am J Addict 2021;30:88-91).
Authors: Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado Journal: Neurosci Biobehav Rev Date: 2010-02-16 Impact factor: 8.989
Authors: Christoph von der Goltz; Anne Koopmann; Christina Dinter; Anne Richter; Christine Rockenbach; Martin Grosshans; Helmut Nakovics; Klaus Wiedemann; Karl Mann; Georg Winterer; Falk Kiefer Journal: Psychoneuroendocrinology Date: 2009-10-13 Impact factor: 4.905
Authors: Roberto Ciccocioppo; Donald R Gehlert; Andrey Ryabinin; Simranjit Kaur; Andrea Cippitelli; Annika Thorsell; Anh D Lê; Philip A Hipskind; Chafiq Hamdouchi; Jianliang Lu; Erik J Hembre; Jeffrey Cramer; Min Song; David McKinzie; Michelle Morin; Daina Economidou; Serena Stopponi; Nazzareno Cannella; Simone Braconi; Marsida Kallupi; Giordano de Guglielmo; Maurizio Massi; David T George; Jody Gilman; Jacqueline Hersh; Johannes T Tauscher; Stephen P Hunt; Daniel Hommer; Markus Heilig Journal: Alcohol Date: 2009-11 Impact factor: 2.405
Authors: Brendan J Tunstall; Dean Kirson; Lia J Zallar; Sam A McConnell; Janaina C M Vendruscolo; Chelsea P Ho; Christopher S Oleata; Sophia Khom; Maurice Manning; Mary R Lee; Lorenzo Leggio; George F Koob; Marisa Roberto; Leandro F Vendruscolo Journal: PLoS Biol Date: 2019-04-16 Impact factor: 8.029
Authors: Ana P Oliveira; Luan K M Souza; Thiago S L Araújo; Simone de Araújo; Kerolayne M Nogueira; Francisca Beatriz M Sousa; Renan O Silva; Dvison M Pacífico; Conceição S Martins; Gerly Anne de C Brito; Marcellus H L P Souza; Jand Venes R Medeiros Journal: Nutrients Date: 2019-01-21 Impact factor: 5.717
Authors: Olga V Roschina; Lyudmila A Levchuk; Anastasiia S Boiko; Ekaterina V Michalitskaya; Elena V Epimakhova; Innokentiy S Losenkov; German G Simutkin; Anton J M Loonen; Nikolay A Bokhan; Svetlana A Ivanova Journal: J Clin Med Date: 2021-12-03 Impact factor: 4.241
Authors: Jillian M Rung; Quintin A Kidder; Marilyn Horta; H P Nazarloo; C Sue Carter; Meredith S Berry; Natalie C Ebner Journal: Brain Behav Date: 2022-02-11 Impact factor: 2.708